FDA accepts sBLA for Keytruda to treat primary mediastinal B cell lymphoma

Merck & Co. Inc. (NYSE:MRK) said FDA accepted for review an sBLA for Keytruda pembrolizumab (MK-3475) to

Read the full 175 word article

User Sign In